The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Open accessAbstract
Biological barriers to drug transport prevent successful accumulation of nanotherapeutics specifically at diseased sites, limiting efficacious responses in disease processes ranging from cancer to inflammation. Although substantial research efforts have aimed to incorporate multiple functionalities and moieties within the overall nanoparticle design, many of these strategies fail to adequately address these barriers. Obstacles, such as nonspecific distribution and inadequate accumulation of therapeutics, remain formidable challenges to drug developers. A reimagining of conventional nanoparticles is needed to successfully negotiate these impediments to drug delivery. Site-specific delivery of therapeutics will remain a distant reality unless nanocarrier design takes into account the majority, if not all, of the biological barriers that a particle encounters upon intravenous administration. By successively addressing each of these barriers, innovative design features can be rationally incorporated that will create a new generation of nanotherapeutics, realizing a paradigmatic shift in nanoparticle-based drug delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nanoparticles will accumulate in the liver if their sizes are comparable to the size of vascular fenestration of the liver (50–100 nm) or end up in the spleen if their sizes are close to interendothelial cell slits of the spleen (100–200 nm).217”
From The Pursuit of Shortwave Infrared-Emitting Nanoparticles with Bright Fluorescence through Molecular Design and Excited-State Engineering of Molecular Aggregates (2022) · cites this paper as [217]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing the BBB with various nanoparticles, such as liposomes, cationic polymers, inorganic nanoparticles, and nanocapsules, has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing the BBB with various nanoparticles, such as liposomes, cationic polymers, inorganic nanoparticles, and nanocapsules, has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among a number of approaches, crossing the BBB with various nanoparticles has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredIn the citing paper
“To demonstrate the colloidal stability of the NP-Pep, we determined the zeta potential (ζ-potential) of the NP-Pep suspended in 0.1× PBS buffer (pH 7.4) to be ~−38 mV, which has been previously shown to be both ideal for serum protein applications and sufficient for electrostatic repulsive forces to dominate over the van der Waals force, such that agglomeration is suppressed (Supplementary Fig. 11”
From Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum (2020) · cites this paper as [45]
In the citing paper
“For example, nanomaterial properties such as size, geometry, material composition and surface chemistry can greatly influence the interactions of the nanomaterials with biological systems49,50.”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,029
Zhu, L., Zhou, Z., Mao, H. Z., & Yang, L. P. H. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0316 · Cited by 268
Strategies to Improve Cancer Photothermal Therapy Mediated by Nanomaterials
de Melo‐Diogo, D., Pais‐Silva, C., Dias, D. R., Moreira, A. F., & Correia, I. J. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700073 · Cited by 271
Hyaluronic acid and albumin based nanoparticles for drug delivery
Lei, C., Liu, X.-R., Chen, Q., Li, Y., Zhou, J., Zhou, L.-Y., & Zou, T. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.033 · Cited by 271
Harnessing Endogenous Stimuli for Responsive Materials in Theranostics
Cook, A. B., & Decuzzi, P. (2021) · ACS Nano · doi:10.1021/acsnano.0c09115 · Cited by 273
Carbon nanotubes in biomedical applications: current status, promises, and challenges
Murjani, B. O., Kadu, P. S., Bansod, M., Vaidya, S. S., & Yadav, M. D. (2022) · Carbon letters · doi:10.1007/s42823-022-00364-4 · Cited by 265
The mechanisms of nanoparticle delivery to solid tumours
Nguyen, L. N. M., Ngo, W., Lin, Z. P., Sindhwani, S., MacMillan, P., Mladjenovic, S. M., & Chan, W. C. W. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00154-9 · Cited by 288
“Since the mechanism was considered resolved, nanoparticle design focused on tumour cell targeting (with antibodies, aptamers and other moieties) or multifunctionality 26,28,161,162 .”
Formation of the Protein Corona: The Interface between Nanoparticles and the Immune System
Barbero, F., Russo, L., Vitali, M., Piella, J., Salvo, I., Borrajo, M. L., Busquets-Fité, M., Grandori, R., Bastús, N. G., Casals, E., et al. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.10.001 · Cited by 263
Parayath, N. N., Parikh, A. B., & Amiji, M. M. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b00689 · Cited by 263
Unlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery
Elliott, R. O., & He, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010122 · Cited by 268
Immunogenicity of Extracellular Vesicles
Xia, Y., Zhang, J., Liu, G., & Wolfram, J. (2024) · Advanced Materials · doi:10.1002/adma.202403199 · Cited by 274
Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities
Agrahari, V., & Agrahari, V. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.047 · Cited by 276
Dogra, P., Adolphi, N. L., Wang, Z., Lin, Y., Butler, K. S., Durfee, P. N., Croissant, J. G., Noureddine, A., Coker, E. N., Bearer, E. L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06730-z · Cited by 263
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Drug Delivery to the Brain across the Blood–Brain Barrier Using Nanomaterials
Tsou, Y., Zhang, X., Zhu, H., Syed, S., & Xu, X. (2017) · Small · doi:10.1002/smll.201701921 · Cited by 263
Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems
Su, S., & Kang, P. M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090837 · Cited by 269
“Without specific targeting functionalization, most nanocarriers depend on their small size to reach the disease site by passive accumulation and retention [77].”
BackgroundHuang, K., Hsu, F., Qiu, J. T., Chern, G., Lee, Y.-A., Chang, C., Huang, Y., Sung, Y., Chiang, C.-C., Huang, R.-L., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax5032 · Cited by 262
“To overcome these challenges, nanoscale formulations were designed and used to encapsulate the therapeutic genetic cargoes with enhanced stability, controlled cargo release properties, and increased transfection activity (13, 14).”
BackgroundAdvances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy
Guevara, M. L., Persano, F., & Persano, S. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.589959 · Cited by 261
Huda, M. N., Nafiujjaman, M., Deaguero, I. G., Okonkwo, J., Hill, M. L., Kim, T. H., & Nurunnabi, M. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00217 · Cited by 268
A simple improved desolvation method for the rapid preparation of albumin nanoparticles
Jahanban‐Esfahlan, A., Dastmalchi, S., & Davaran, S. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.05.032 · Cited by 256
Lv, G., Guo, W., Zhang, W., Zhang, T., Li, S., Chen, S., Eltahan, A. S., Wang, D., Wang, Y., Zhang, J., et al. (2016) · ACS Nano · doi:10.1021/acsnano.6b05419 · Cited by 256
Microfluidic-assisted fabrication of carriers for controlled drug delivery
Liu, D., Zhang, H., Fontana, F., Hirvonen, J. J., & Santos, H. A. (2017) · Lab on a Chip · doi:10.1039/c7lc00242d · Cited by 261
Li, Y., Liu, G., Ma, J., Lin, J., Lin, H., Su, G., Chen, D., Ye, S., Chen, X. S., Zhu, X., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.05.011 · Cited by 255
Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects
Zhang, P., Xiao, Y., Sun, X. F., Lin, X., Koo, S., Yaremenko, A. V., Qin, D., Kong, N., Farokhzad, O. C., & Tao, W. (2022) · Med · doi:10.1016/j.medj.2022.12.001 · Cited by 265
Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery
Waheed, S., Li, Z., Zhang, F., Chiarini, A., Armato, U., & Wu, J. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01605-4 · Cited by 259
“Thus, NPs oftenest penetrate the cell membrane via active transport [4, 89].”
BackgroundManipulation and Motion of Organelles and Single Molecules in Living Cells
Nørregaard, K., Metzler, R., Ritter, C. M., Berg‐Sørensen, K., & Oddershede, L. B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00638 · Cited by 253
“148 Another factor a ff ecting the endocytotic e ffi ciency is surface charge 149 that can readily be adjusted by correct surface functionalization by neutralizing molecules (see discussion in section 4.2.2).”
BackgroundInfluentialThe blood clearance kinetics and pathway of polymeric micelles in cancer drug delivery
Sun, X., Wang, G., Zhang, H., Hu, S., Liu, X., Tang, J., & Shen, Y. (2018) · ACS Nano · doi:10.1021/acsnano.8b02830 · Cited by 253
Nanomedicines for renal disease: current status and future applications
Kamaly, N., He, C., Ausiello, D. A., & Farokhzad, O. C. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.156 · Cited by 256
Modulation of the Cellular Uptake of DNA Origami through Control over Mass and Shape
Bastings, M. M. C., Anastassacos, F. M., Ponnuswamy, N., Leifer, F., Cuneo, G., Lin, C., Ingber, D. E., Ryu, J. H., & Shih, W. M. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b00660 · Cited by 252
Recent advances in "smart" delivery systems for extended drug release in cancer therapy
Kalaydina, R.-V., Bajwa, K., Qorri, B., DeCarlo, A., & Szewczuk, M. R. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s168053 · Cited by 250
“9,10 The widespread use of NPs in cancer therapy has also been precluded due to traditional NPs exhibiting suboptimal stability in the body, slow intracellular drug release, low accumulation in tumor sites, and low cellular uptake and aspecific targeting.”
Drug Delivery Strategies for Platinum-Based Chemotherapy
Browning, R. J., Reardon, P. J. T., Parhizkar, M., Pedley, R. B., Edirisinghe, M. J., Knowles, J. C., & Stride, E. (2017) · ACS Nano · doi:10.1021/acsnano.7b04092 · Cited by 252
Yuan, Y., Zhang, J., Qi, X., Li, S., Liu, G., Siddhanta, S., Barman, I., Song, X., McMahon, M. T., & Bulte, J. W. M. (2019) · Nature Materials · doi:10.1038/s41563-019-0503-4 · Cited by 250
Lee, C., Hwang, H. S., Lee, S., Kim, B., Kim, J. O., Oh, K. T., Lee, E. S., Choi, H., & Youn, Y. S. (2017) · Advanced Materials · doi:10.1002/adma.201605563 · Cited by 248
Nanotechnology intervention of the microbiome for cancer therapy
Song, W., Anselmo, A. C., & Huang, L. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0589-5 · Cited by 248
Identification of Receptor Binding to the Biomolecular Corona of Nanoparticles
Lara, S., Alnasser, F., Polo, E., Garry, D., Giudice, C. L., Hristov, D. R., Rocks, L., Salvati, A. L., Yan, Y., & Dawson, K. A. (2017) · ACS Nano · doi:10.1021/acsnano.6b07933 · Cited by 248
Green synthesis of nanoparticles: A greener approach for a cleaner future
Pal, G., Rai, P., & Pandey, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-102579-6.00001-0 · Cited by 260
Advanced functional polymer materials
Wang, K., Amin, K., An, Z., Cai, Z., Chen, H., Chen, H., Dong, Y., Feng, X., Fu, W., Gu, J., et al. (2020) · Materials Chemistry Frontiers · doi:10.1039/d0qm00025f · Cited by 248
Cui, Y., Zhang, M., Zeng, F., Jin, H., Xu, Q., & Huang, Y. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b10175 · Cited by 243
Hydroxyapatite Nanoparticles in Drug Delivery: Physicochemistry and Applications
Ochoa, S. L., Ortega-Lara, W. D. L., & Guerrero-Beltrán, C. E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101642 · Cited by 243
“In this sense, biomaterials can be categorized into polymers, liposomes, micelles, dendrimers, and calcium phosphate (CaP) nanoparticles, where each will show a different type of bioactivity [3].”
BackgroundCarbon Nanomaterial Fluorescent Probes and Their Biological Applications
Krasley, A. T., Li, E., Galeana, J. M., Bulumulla, C., Beyene, A. G., & Demirer, G. S. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00581 · Cited by 258
Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications
Mosayebi, J., Kiyasatfar, M., & Laurent, S. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700306 · Cited by 250
From Marine Origin to Therapeutics: The Antitumor Potential of Marine Algae-Derived Compounds
Alves, C., Silva, J., Pintéus, S., Gaspar, H., Alpoim, M. C., Botana, L. M., & Pedrosa, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00777 · Cited by 249
Metal Oxide Nanoparticles: Review of Synthesis, Characterization and Biological Effects
Negrescu, A. M., Killian, M. S., Raghu, S. N. V., Schmuki, P., Mazare, A., & Cîmpean, A. (2022) · Journal of Functional Biomaterials · doi:10.3390/jfb13040274 · Cited by 258
Activating Drugs with Sound: Mechanisms Behind Sonodynamic Therapy and the Role of Nanomedicine
Choi, V., Rajora, M. A., & Zheng, G. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00029 · Cited by 237
Targeting memory T cell metabolism to improve immunity
Corrado, M., & Pearce, E. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148546 · Cited by 250
“This strategy includes drug delivery using nanoparticles (171), oncolytic viruses (172), use of metabolically engineered CAR T cells (173, 174), or precursor drugs selectively activated in the TME (154).”
MethodEjigah, V., Owoseni, O., Backer, P. B., Ogundipe, O. D., Fisusi, F. A., & Adesina, S. K. (2022) · Polymers · doi:10.3390/polym14132601 · Cited by 251
Liu, D., Zhang, H., Fontana, F., Hirvonen, J. J., & Santos, H. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.08.003 · Cited by 241
“To facilitate targeting drug delivery, it is necessary to optimize the physicochemical parameters for the fabricated nanoparticles, such as shape, average size, surface charge, and surface composition [36, 37].”
BackgroundHu, G., Guo, M., Xu, J., Wu, F., Fan, J., Huang, Q., Yang, G., Lv, Z., Wang, X., & Jin, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01998 · Cited by 241
“NPs cannot exert their therapeutic effects, involving extravasation, cellular membrane traversal and cellular internalization, until they reached their intended target (44).”
BackgroundThe Coppery Age: Copper (Cu)‐Involved Nanotheranostics
Dong, C., Feng, W., Xu, W., Yu, L., Xiang, H., Chen, Y., & Zhou, J. (2020) · Advanced Science · doi:10.1002/advs.202001549 · Cited by 236
Deng, J., Xu, S., Hu, W., Xun, X., Zheng, L., & Su, M. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.048 · Cited by 234
Getting Drugs Across Biological Barriers
Yang, R., Wei, T., Goldberg, H., Wang, W., Cullion, K., & Kohane, D. S. (2017) · Advanced Materials · doi:10.1002/adma.201606596 · Cited by 249
Additive Manufacturing of Precision Biomaterials
Guzzi, E. A., & Tibbitt, M. W. (2019) · Advanced Materials · doi:10.1002/adma.201901994 · Cited by 246
Smart drug delivery systems for precise cancer therapy
Wang, X., Li, C., Wang, Y., Chen, H., Zhang, X., Luo, C., Zhou, W., Li, L., Teng, L., Yu, H., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.013 · Cited by 256
Engineering Biomimetic Platesomes for pH‐Responsive Drug Delivery and Enhanced Antitumor Activity
Liu, G., Zhao, X., Zhang, Y., Xu, J., Xu, J., Li, Y., Min, H., Shi, J. Y., Zhao, Y., Wei, J., et al. (2019) · Advanced Materials · doi:10.1002/adma.201900795 · Cited by 236
Qin, W., Wang, C., Ma, Y., Shen, M., Li, J., Jiao, K., Tay, F. R., & Niu, L. (2020) · Advanced Materials · doi:10.1002/adma.201907833 · Cited by 242
Campbell, F., Bos, F. L., Sieber, S., Arias‐Alpizar, G., Koch, B. E. V., Huwyler, J., Kros, A., & Bussmann, J. (2018) · ACS Nano · doi:10.1021/acsnano.7b06995 · Cited by 236
Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy
Fu, Z., & Xiang, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239123 · Cited by 246
Multicellular Tumor Spheroids (MCTS) as a 3D In Vitro Evaluation Tool of Nanoparticles
Lu, H., & Stenzel, M. H. (2018) · Small · doi:10.1002/smll.201702858 · Cited by 234
Wang, Z., Ju, Y., Ali, Z., Yin, H. Y., Sheng, F., Lin, J., Wang, B., & Hou, Y. (2019) · Nature Communications · doi:10.1038/s41467-019-12142-4 · Cited by 233
Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery
Zelepukin, I. V., Shevchenko, K. G., & Deyev, S. M. (2024) · Nature Communications · doi:10.1038/s41467-024-48838-5 · Cited by 248
“3j) 4 , or rapid drug unloading in the tumour-surrounding microenvironment 95 .”
BackgroundLigand density on nanoparticles: A parameter with critical impact on nanomedicine
Alkilany, A. M., Zhu, L., Weller‡, H., Mews, A., Parak, W. J., Barz, M., & Feliu, N. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.010 · Cited by 238
Boosting Cancer Therapy with Organelle-Targeted Nanomaterials
Gao, P., Pan, W., Li, N., & Tang, B. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b01370 · Cited by 231
Zhang, L., He, F.-J., Gao, L., Cong, M., Sun, J., Xu, J., Wang, Y., Hu, Y., Asghar, S., Hu, L., et al. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s293067 · Cited by 234
Gold nanoparticles (GNPs) in biomedical and clinical applications: A review
Anik, M. I., Mahmud, N., Masud, A. A., & Hasan, M. (2021) · Nano Select · doi:10.1002/nano.202100255 · Cited by 244
Hyperthermia using nanoparticles – Promises and pitfalls
Kaur, P., Aliru, M. L., Chadha, A. S., Asea, A. A. A., & Krishnan, S. (2016) · International Journal of Hyperthermia · doi:10.3109/02656736.2015.1120889 · Cited by 232
Designing nanomedicine for immuno-oncology
Jiang, W., Roemeling, C. A. V., Chen, Y., Qie, Y., Liu, X., Chen, J., & Kim, B. Y. S. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0029 · Cited by 230
Cell Membrane-Camouflaged Nanoparticles as Drug Carriers for Cancer Therapy
Xu, C., Ye, P.-J., Zhou, Y., He, D., Wei, H., & Yu, C. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.01.036 · Cited by 229
Li, M.-L., Long, S.-R., Kang, Y., Guo, L.-Y., Wang, J.-Y., Fan, J.-L., Du, J.-J., & Peng, X.-J. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b09117 · Cited by 196
A Comprehensive Review of Cancer MicroRNA Therapeutic Delivery Strategies
Forterre, A. V., Komuro, H., Aminova, S., & Harada, M. (2020) · Cancers · doi:10.3390/cancers12071852 · Cited by 233
Nano-Enhanced Drug Delivery and Therapeutic Ultrasound for Cancer Treatment and Beyond
Tharkar, P., Varanasi, R., Wong, W. S. F., Jin, C. T., & Chrzanowski, W. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00324 · Cited by 234
“…systems removes major limitations of conventional drug delivery systems, including: – Insufficient uptake and accumulation of nanoparticles by cells (Blanco et al., 2015), – Limited amount of drug delivered or released from nanoparticles (Du et al., 2011), and – Targeted specific delivery of drug…”
BackgroundA Crosslinked Nucleic Acid Nanogel for Effective siRNA Delivery and Antitumor Therapy
Ding, F., Mou, Q., Ma, Y., Pan, G., Guo, Y., Tong, G., Choi, C. H. J., Zhu, X., & Zhang, C. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201711242 · Cited by 227
Sabit, H., Pawlik, T. M., Radwan, F., Abdel-Hakeem, M., Abdel-Ghany, S., Wadan, A.-H. S., Elzawahri, M., El-Hashash, A., & Arneth, B. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02357-z · Cited by 239
Enhancement of EPR Effect for Passive Tumor Targeting: Current Status and Future Perspectives
Vagena, I.-A., Malapani, C., Gatou, Μ.-A., Lаgopati, N., & Pavlatou, E. A. (2025) · Applied Sciences · doi:10.3390/app15063189 · Cited by 252
Gold Nanoclusters for Targeting Methicillin‐Resistant Staphylococcus aureus In Vivo
Xie, Y., Liu, Y., Yang, J., Liu, Y., Hu, F., Zhu, K., & Jiang, X. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201712878 · Cited by 223
Zhang, Y., Wang, F., Li, M., Yu, Z., Qi, R., Ding, J., Zhang, Z., & Chen, X. (2018) · Advanced Science · doi:10.1002/advs.201700821 · Cited by 221
Macrophage-Specific in Vivo Gene Editing Using Cationic Lipid-Assisted Polymeric Nanoparticles
Luo, Y., Xu, C., Li, H., Cao, Z., Liu, J., Wang, J., Du, X., Yang, X., Gu, Z., & Wang, J. (2018) · ACS Nano · doi:10.1021/acsnano.7b07874 · Cited by 223
Akombaetwa, N., Ilangala, A. B., Thom, L., Memvanga, P. B., Witika, B. A., & Buya, A. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020656 · Cited by 233
“Achieving the desired response to therapeutic agents in a wide range of disease states largely depends on direct delivery of the drug to a specific site [55].”
BackgroundEngineering gold-based radiosensitizers for cancer radiotherapy
Goswami, N., Luo, Z., Yuan, X. F., Leong, D. T., & Xie, J. (2017) · Materials Horizons · doi:10.1039/c7mh00451f · Cited by 219
Durfee, P. N., Lin, Y.-S., Dunphy, D. R., Muñiz, A. J., Butler, K. S., Humphrey, K. R., Lokke, A. J., Agola, J. O., Chou, S. S., Chen, I.-M., et al. (2016) · ACS Nano · doi:10.1021/acsnano.6b02819 · Cited by 219
“and negatively charged vesicles onto glass as a function of pH (3-12) and ionic strength (0-90”
BackgroundRosenkrans, Z. T., Sun, T., Jiang, D., Chen, W., Barnhart, T. E., Zhang, Z., Ferreira, C. A., Wang, X., Engle, J. W., Huang, P., et al. (2020) · Advanced Science · doi:10.1002/advs.202000420 · Cited by 219
Kaczmarek, J. C., Kauffman, K. J., Fenton, O. S., Sadtler, K., Patel, A. K., Heartlein, M. W., DeRosa, F., & Anderson, D. G. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b02917 · Cited by 218
Ma, F., Yang, L., Sun, Z., Chen, J., Rui, X., Glass, Z., & Xu, Q. (2020) · Science Advances · doi:10.1126/sciadv.abb4429 · Cited by 218
“…BBB with various nano-particles, such as liposomes, cationic polymers, inorganic nano-particles, and nanocapsules, has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable ( 15 , 18 , 19 ).”
Semiconducting Photothermal Nanoagonist for Remote-Controlled Specific Cancer Therapy
Xu, Z. J., Xie, C., Jiang, Y., Ai, X., Xing, B., & Pu, K. (2018) · Nano Letters · doi:10.1021/acs.nanolett.7b05292 · Cited by 218
Top-down fabrication of shape-controlled, monodisperse nanoparticles for biomedical applications
Fu, X., Cai, J., Zhang, X., Li, W., Ge, H., & Hu, Y. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.006 · Cited by 226
Triggered ferroptotic polymer micelles for reversing multidrug resistance to chemotherapy
Gao, M., Deng, J., Liu, F., Fan, A., Wang, Y., Wu, H., Ding, D., Kong, D., Wang, Z., Peer, D., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119486 · Cited by 218
Improving cancer therapy through the nanomaterials-assisted alleviation of hypoxia
Sahu, A., Kwon, I., & Tae, G. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119578 · Cited by 219
Particle toxicology and health - where are we?
Riediker, M., Zink, D., Kreyling, W. G., Oberdörster, G., Elder, A. C. P., Graham, U. M., Lynch, I., Duschl, A., Ichihara, G., Ichihara, S., et al. (2019) · Particle and Fibre Toxicology · doi:10.1186/s12989-019-0302-8 · Cited by 233
“Blanco, Shen and Ferrari looked at effect of size (<5nm, 20-150nm and > 150nm), shape (20-150nm spheres, rods and discs) and surface charge (20-150nm spheres with negative, neutral or positive) on where the NPs accumulated [138].”
Endosomal Size and Membrane Leakiness Influence Proton Sponge-Based Rupture of Endosomal Vesicles
Vermeulen, L. M. P., Brans, T., Samal, S. K., Dubruel, P., Demeester, J., Smedt, S. C. D., Remaut, K., & Braeckmans, K. (2018) · ACS Nano · doi:10.1021/acsnano.7b07583 · Cited by 218
Nanomaterials for Cancer Precision Medicine
Wang, Y., Sun, S., Zhang, Z., & Shi, D. (2018) · Advanced Materials · doi:10.1002/adma.201705660 · Cited by 213
Tabish, T. A., Dey, P., Mosca, S., Salimi, M., Palombo, F., Matousek, P., & Stone, N. (2020) · Advanced Science · doi:10.1002/advs.201903441 · Cited by 216
Wang, L., Huang, J., Chen, H., Wu, H. C., Xu, Y., Li, Y., Yi, H. L., Wang, Y. A., Yang, L. P. H., & Mao, H. Z. (2017) · ACS Nano · doi:10.1021/acsnano.7b00038 · Cited by 215
Ahn, E.-Y., Jin, H., & Park, Y. (2019) · Materials Science and Engineering C · doi:10.1016/j.msec.2019.03.095 · Cited by 218
Zhang, Q., Wei, W., Wang, P., Zuo, L., Li, F., Xu, J., Xi, X., Gao, X., Ma, G., & Xie, H. (2017) · ACS Nano · doi:10.1021/acsnano.7b04955 · Cited by 213
Black Phosphorus Quantum Dots with Renal Clearance Property for Efficient Photodynamic Therapy
Guo, T., Wu, Y., Lin, Y., Xu, X., Lian, H., Huang, G., Liu, J. H., Wu, X., & Yang, H. (2017) · Small · doi:10.1002/smll.201702815 · Cited by 211
Liu, J., Liang, H., Li, M., Luo, Z. Y., Zhang, J., Guo, X., & Cai, K. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.12.003 · Cited by 212
“However, only a small proportion of the total dministered nanotherapeutics finally reach to tumor tissue [2], since they encou nter a series of biological barriers during the transport process in vivo, such as renal clearance, plasma proteins adsorption, mononuclear phagocytes system (MPS) cle arance, cell membrane tr…”
BackgroundChen, D., Zhang, G., Li, R., Guan, M., Wang, X., Zou, T., Zhang, Y., Wang, C., Shu, C., Hong, H., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b12025 · Cited by 211
Size, shape, and flexibility influence nanoparticle transport across brain endothelium under flow
Nowak, M., Brown, T. D., Graham, A., Helgeson, M. E., & Mitragotri, S. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10153 · Cited by 210
“sate into tumor tissues, but only smaller particles (<30 nm) are cleared easily, though the size range can vary substantially depending on the tumor type.(10)”
BackgroundNanomaterial surface modification toolkit: Principles, components, recipes, and applications
Kaymaz, S. V., Malekzad, H., Sarıgül, H., Soylukan, C., Akyüz, L., & Yüce, M. (2023) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2023.103035 · Cited by 217
Bacterial Biofilm in Chronic Wounds and Possible Therapeutic Approaches
Cavallo, I., Sivori, F., Mastrofrancesco, A., Abril, E., Pontone, M., Domenico, E. G. D., & Pimpinelli, F. (2024) · Biology · doi:10.3390/biology13020109 · Cited by 234
“Nanoparticles (NPs) can cross biological barriers and, therefore, can efficiently release the antimicrobial agent directly within biofilms [117,118].”
BackgroundMolecular Communication and Nanonetwork for Targeted Drug Delivery: A Survey
Chude-Okonkwo, U. A. K., Malekian, R., Maharaj, B. T., & Vasilakos, A. V. (2017) · IEEE Communications Surveys & Tutorials · doi:10.1109/comst.2017.2705740 · Cited by 216
“It is shown in [330] that unlike spherical nanoparticles, nonspherical particles, such as those possessing discoidal geometries, are more prone to tumbling and”
BackgroundInfluentialMulti‐Functional Liposome: A Powerful Theranostic Nano‐Platform Enhancing Photodynamic Therapy
Cheng, X., Gao, J., Ding, Y., Lu, Y., Wei, Q., Cui, D., Fan, J., Li, X., Zhu, E., Lu, Y., et al. (2021) · Advanced Science · doi:10.1002/advs.202100876 · Cited by 209
Metadata
- Authors
- Blanco, E., Shen, H., & Ferrari, M.
- Affiliations
- Houston Methodist (US)
- Venue
- Nature Biotechnology
- Published
- 2015-09
- Volume
- 33
- Issue
- 9
- Pages
- 941-951
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC4978509
- OpenAlex
- W2143463421
- Cited by
- 7,002
- References
- 123
- Citations by year
- 2026: 729 · 2025: 685 · 2024: 772 · 2023: 712 · 2022: 739 · 2021: 713 · 2020: 736 · 2019: 652 · 2018: 611 · 2017: 436 · 2016: 198 · 2015: 15
- FWCI
- 150.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (U54CA151668, U54CA143837)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- nanoparticle drug delivery, nanocarrier design, biological barriers, local drug delivery, intravenous administration, tumor accumulation, cancer therapeutics, inflammation, nanotherapeutics
- MeSH terms
- Biocompatible Materials, Drug Compounding, Drug Design, Nanomedicine, Nanocapsules
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
